Inducer Treatment AGEs IC50 (µM)
Glucose 1 619 ± 8.32a***
2 593 ± 7.45b
3 545 ± 10.43
4 712 ± 15.21c**
5 1003 ± 25.28c*
6 815 ± 7.87 a**
7 1065 ± 23.65 c*
8 512 ± 18.23
Aminoguanidine 482 ± 43.21
Phloroglucinol 553 ± 29.42
Methylglyoxal 1 1169 ± 12.45 a
2 1032 ± 21.67
3 986 ± 19.54
4 1305 ± 46.28 b**
5 1701 ± 52.34 a**
6 1659 ± 48.64 c***
7 1824 ± 38.90 b*
8 875 ± 19.76
Aminoguanidine 910 ± 20.37
Phloroglucinol 1019 ± 32.48
           %
Lysozyme/ribose 1 47.2 ± 5.43 c
2 51.9 ± 4.86
3 57.7 ± 3.98
4 42.5 ± 4.65 a
5 36.3 ± 4.75 a
6 30.9 ± 1.98 b
7 29.8 ± 3.56 a
8 60.3 ± 2.74
Pyridoxamine 58.3 ± 5.10
Data are mean ± standard deviation of triplicate tests. The fluorescence intensity was measured at ex 370 nm and em 470 nm. The intensity of each blank was subtracted from the intensity of each sample. Concentration of an inhibitor required to inhibit 50% of the control. Calculated from linear regression equation. ap<0.05, bp<0.01, cp< 0.001; vs control aminoguanidine or *p<0.05, **p<0.01, ***p<0.001; vs control controlphloroglucinol or orpyridoxamine n.
Table 1: The inhibitory effects of 1-8 and aminoguanidine on the formation of advanced glycation end products (AGEs), in vitro induced by glucose, methylglioxal and ribose.